--- title: "RCKT 最后期限：Rosen 律师事务所敦促 Rocket 制药公司（NASDAQ: RCKT）的股东，如果损失超过 10 万美元，请联系该事务所以了解他们的权利信息" description: "Rosen 律师事务所呼吁 Rocket Pharmaceuticals, Inc.（纳斯达克代码：RCKT）的股东，如果他们的损失超过 10 万美元，请与他们联系以了解自己的权利。针对在 2024 年 9 月 17 日至 2025 年 5 月 26 日期间购买证券的投资者，已提起集体诉讼，指控该公司误导投资者关于其 RP-A501 治疗的有效性和安全性。希望领导该集体诉讼的股东必须在 2025 " type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/251303959.md" published_at: "2025-08-02T21:25:32.000Z" --- # RCKT 最后期限：Rosen 律师事务所敦促 Rocket 制药公司（NASDAQ: RCKT）的股东，如果损失超过 10 万美元，请联系该事务所以了解他们的权利信息 > Rosen 律师事务所呼吁 Rocket Pharmaceuticals, Inc.（纳斯达克代码：RCKT）的股东，如果他们的损失超过 10 万美元，请与他们联系以了解自己的权利。针对在 2024 年 9 月 17 日至 2025 年 5 月 26 日期间购买证券的投资者，已提起集体诉讼，指控该公司误导投资者关于其 RP-A501 治疗的有效性和安全性。希望领导该集体诉讼的股东必须在 2025 年 8 月 11 日之前提交动议。Rosen 律师事务所以风险代理费用的方式运营，确保股东无需支付前期费用 **RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals,** **Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights** Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501’s clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event (“SAE”); (4) accordingly, RP-A501’s safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View source version on businesswire.com: https://www.businesswire.com/news/home/20250802688652/en/ ### Related Stocks - [RCKT.US - Rocket制药](https://longbridge.com/zh-CN/quote/RCKT.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 10:08 ETRokt Joins American Heart Association's "Go Red. Shop with Heart" Initiative, Marks Kickoff at NYSE Bell Ringing | Rokt, a leading ecommerce technology company, has joined the American Heart Association's "Go Red. Shop with Heart" init | [Link](https://longbridge.com/zh-CN/news/275145288.md) | | Rocket Doctor AI Grants Stock Options and Restricted Share Units to Consultants | Rocket Doctor AI Inc. has granted 33,353 stock options at $0.77 per share and 205,065 restricted share units to consulta | [Link](https://longbridge.com/zh-CN/news/274366738.md) | | Rocket Doctor Engages Danayi Capital for Digital Marketing Services \| AIRDF Stock News | Rocket Doctor AI Inc. has engaged Danayi Capital Corp. for digital marketing services for two months starting February 9 | [Link](https://longbridge.com/zh-CN/news/274367082.md) | | Rocket Doctor AI Secures In-Network Contract With Major U.S. Insurer Covering 175,000 California Members | Rocket Doctor AI Inc. has secured a contract with a major U.S. insurer, expanding its digital health platform to 175,000 | [Link](https://longbridge.com/zh-CN/news/273874717.md) | | Wedbush Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT) | Wedbush analyst Yun Zhong has reaffirmed a Buy rating on Rocket Pharmaceuticals (RCKT) with a price target of $16.00. Zh | [Link](https://longbridge.com/zh-CN/news/264863677.md) | --- > **免责声明**：本文内容仅供参考，不构成任何投资建议。